Biomeme
Novo Nordisk

Saxenda

Liraglutide 3.0 mg

First-generation daily GLP-1 for weight management — superseded by weekly options.

Chronic Weight Management 8.0% avg weight loss
68 C+

Evidence Score

Score Breakdown

mRNA Monitoring Compatibility 16/20
Weight Loss Efficacy 10/20
Tolerability 13/20
Cardiovascular Evidence 15/20
Muscle Preservation 14/20

Overview

Saxenda (liraglutide 3.0 mg) is a once-daily injectable GLP-1 receptor agonist approved in 2014 for chronic weight management. As a first-generation agent, it proved the viability of GLP-1 therapy for obesity in the SCALE trial program, though it has largely been superseded by newer once-weekly and co-agonist options.

Mechanism of Action

Once-daily GLP-1 receptor agonist that slows gastric emptying, promotes central satiety, and enhances glucose-dependent insulin secretion.

Clinical Evidence

The SCALE clinical trial program demonstrated 8.0% mean weight loss at 56 weeks versus 2.6% for placebo, establishing the foundation for modern incretin-based obesity medicine.

mRNA Monitoring Insight

Biomeme's transcriptomic panel tracks whether systemic inflammatory resolution programs remain active over time during daily liraglutide therapy.

Side Effects & Safety

GI adverse events (nausea, vomiting, diarrhea) requiring daily administration, with higher discontinuation rates than weekly formulations.

FAQ

Is Saxenda still used for weight loss?
While still FDA-approved, most clinicians prefer newer once-weekly medications like Wegovy or Zepbound due to greater weight loss efficacy and once-weekly convenience.

Quick Facts

Generic
Liraglutide 3.0 mg
Manufacturer
Novo Nordisk
Key Trial
SCALE
Score
68/100 (C+)

Sources

  1. [1] SCALE Trial — NEJM 2015

Testing & Guides

Compare Others

Founding Cohort

Track Your Saxenda Response — Cohort Now Forming

Real mRNA data on whether your Saxenda therapy is working. Reserve your spot today to lock in founding pricing before the general public.